Compound research

CJC-1295 / Ipamorelin: A Research Overview

Aminent Labs Research·Updated July 2026·For Research Use Only·6 min read

CJC-1295 and Ipamorelin are synthetic peptides frequently paired as a blend in laboratory investigations of the growth-hormone (GH) axis. This overview summarizes their reported biochemistry and the preclinical, in-vitro, and animal-model contexts in which they have been studied. All material here is provided strictly for research and educational purposes; these peptides are research-use-only (RUO) reagents and are not intended for human or veterinary use, diagnosis, or treatment.

What is CJC-1295 / Ipamorelin?

The blend combines two mechanistically distinct research peptides that act on separate receptor systems governing growth-hormone release, which is why they are often co-formulated as experimental probes of the same signaling axis.

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), based on the modified GRF(1-29) fragment with amino-acid substitutions intended to improve stability against enzymatic degradation in laboratory preparations. Literature distinguishes two commonly referenced forms. The no-DAC form (often labeled "Modified GRF 1-29") is the 29-residue peptide with an approximate molecular weight of ~3,368 Da. The DAC form incorporates a Drug Affinity Complex designed, in the original research, to associate with serum albumin and thereby extend circulating persistence in preclinical models; its molecular weight is higher (~3,647 Da). This DAC vs. no-DAC distinction is significant for researchers because it changes the reported pharmacokinetic profile in animal studies.

Ipamorelin is a synthetic pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, approximate molecular weight ~712 Da) described in the literature as a selective agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). It belongs to the growth-hormone secretagogue peptide class but is noted in early characterization work for its receptor selectivity relative to earlier compounds.

Mechanisms studied in research

The two peptides have been investigated preclinically as ligands for distinct receptor pathways, both of which converge on somatotroph cells of the anterior pituitary in the model systems examined.

GHRH-receptor pathway (CJC-1295): As a GHRH analog, CJC-1295 has been studied in the context of the GHRH receptor, a class-B G-protein-coupled receptor. Research literature describes GHRH-receptor engagement as coupling to Gs and adenylate-cyclase / cAMP signaling in cell and tissue models.

Ghrelin / GHS-R1a pathway (Ipamorelin): Ipamorelin has been characterized in binding and functional studies as an agonist at GHS-R1a. Reports describe this receptor as coupling through Gq/11, phospholipase-C activation, and intracellular calcium mobilization in the cell models studied. Early characterization work also examined its selectivity profile in animal models.

Because GH secretion is pulsatile and modulated by somatostatin, animal-model research has examined how GHRH-receptor and ghrelin-receptor inputs interact with these endogenous rhythms. These descriptions represent reported findings in non-human preclinical systems and should not be read as characterizations of any human physiological outcome.

Areas of preclinical investigation

Published preclinical and in-vitro work on these peptides has spanned several endocrine-research contexts, framed strictly as laboratory research and not as evidence of any human application:

Receptor pharmacology: in-vitro binding, selectivity, and functional (second-messenger) assays characterizing GHRH-receptor and GHS-R1a engagement.
Somatotroph signaling: cell-based studies of GH secretory pathways and the interaction of GHRH-analog and ghrelin-receptor inputs.
Endocrine axis modeling: animal-model investigations of GH pulsatility, feedback regulation, and the modulatory role of somatostatin.
Pharmacokinetic characterization: preclinical work comparing the persistence profiles of DAC and no-DAC CJC-1295 constructs.

None of these research contexts constitutes a demonstrated therapeutic effect, and no benefit for humans is implied or established.

Stability, handling & storage

Research-grade peptides of this type are typically supplied as a lyophilized (freeze-dried) powder. General handling considerations discussed in peptide-research literature include:

Storage of lyophilized material: the dry powder is commonly held refrigerated for shorter-term storage and frozen (e.g., -20 C or colder) for longer-term storage, protected from light and moisture.
Reconstitution for in-vitro work: for laboratory assays, lyophilized peptide is dissolved in an appropriate research-grade solvent suited to the assay. This is a general description of in-vitro laboratory practice and is not a preparation protocol for administration to any organism.
Reconstituted stability: peptides in solution are generally less stable than the lyophilized form; solutions are typically kept cold, and repeated freeze-thaw cycles are minimized.

Because this is a two-component blend, stability and handling considerations apply to both peptides, and their properties may differ.

How research-grade peptides are characterized

Analytical characterization is central to using peptide reagents reliably in research. Reputable research-grade material is typically accompanied by a Certificate of Analysis (COA) documenting identity and purity, supported by standard analytical methods:

HPLC -- used to assess purity, commonly reported as a percentage, and to resolve the peptide from process-related impurities.
Mass spectrometry -- used to confirm molecular identity by matching the measured mass to the expected value for each peptide.
Additional documentation -- a COA may also report appearance, net peptide content, and relevant lot information.

Because this product is a blend, characterization matters for both components: a meaningful COA should address the identity and purity of the CJC-1295 constituent (and specify DAC vs. no-DAC) as well as the Ipamorelin constituent.

How a two-peptide research blend is prepared

A blend is not a single compound, and that shapes both how it is made and how it should be documented. Each peptide is synthesized and purified separately — the 29-residue GHRH analog and the pentapeptide are entirely different synthetic targets with different lengths, different coupling challenges, and different impurity profiles. Only after each component has been made and purified to its own specification are the two combined in a defined ratio and lyophilized together into a single vial.

The practical consequence is that a blend has two identities to confirm, two purity figures to report, and a ratio to establish. A single "≥ 99%" figure on a certificate is ambiguous unless it is clear which component it describes, and a mass-spectrometry trace should show peaks consistent with both peptides. The impurity families that arise during synthesis of each component are the ordinary ones described in Peptide Impurities Explained; the difference here is simply that they can arise twice, independently.

Reading a certificate of analysis for a blend

What a certificate should establish for this product specifically:

Which CJC-1295 form is present. The single most important field. The no-DAC form (commonly labelled Modified GRF 1-29) has an approximate molecular weight of 3,368 Da; the DAC form is roughly 3,647 Da. That difference of several hundred daltons is unambiguous by mass spectrometry, so a certificate should state which form the lot contains and show a mass consistent with it.
Both component masses. Alongside the GHRH-analog mass, a peak consistent with Ipamorelin at approximately 712 Da. Confirming only one component leaves the other undocumented.
The stated ratio. A blend described as 5 mg + 5 mg contains 5 mg of each peptide — 10 mg of total peptide in the vial — rather than 5 mg split between them. Reading the label as a total, or as a per-component figure when it is a total, is a straightforward way to miscalculate every downstream concentration.
Net peptide content. Applies to a blend exactly as to a single peptide: gross vial mass includes residual water, counter-ions, and salts. See Net Peptide Content vs. Purity.

Per-lot reports are published on the certificates of analysis page, and lot documentation accompanies the CJC-1295 / Ipamorelin listing. How to Read a Peptide COA walks through a certificate field by field.

Points of confusion in the literature

DAC versus no-DAC is a different molecule, not a grade. The Drug Affinity Complex modification is a chemical addition that lets the peptide associate with serum albumin, and it changes both the molecular weight and the reported persistence profile in preclinical models. Literature describing one form does not describe the other, and pharmacokinetic figures from DAC studies do not transfer to no-DAC material. Any comparison should start by establishing which form each source used.

"Modified GRF 1-29" and "CJC-1295 no DAC" usually name the same thing. The naming is inconsistent across vendors and papers. Because the two labels are frequently used for the same 29-residue analog, the molecular weight on the certificate is a more reliable identifier than the product name.

A blend is not a compound with its own literature. The published research characterizes these peptides individually. Reports about the combination describe two agents studied together, not a distinct molecular entity with its own established profile, and the two components act through different receptors — a GHRH receptor and the ghrelin/GHS-R1a receptor.

Blend documentation is easy to under-specify. Because a single vial can be sold with a certificate that meaningfully characterizes only the more expensive or more recognizable component, it is worth confirming that both peptides appear in the analytical data rather than assuming a single purity figure covers the vial. The general question of how to verify that a report is genuine and complete is covered in Third-Party Peptide Testing.

FAQ

What is CJC-1295 / Ipamorelin? It is a research-use-only peptide blend combining CJC-1295 -- a synthetic GHRH analog available in DAC and no-DAC forms -- with Ipamorelin, a synthetic pentapeptide described as a selective ghrelin / GHS-R1a receptor agonist. The two are studied together as tools for investigating distinct but convergent inputs to the growth-hormone axis in preclinical and in-vitro systems.

Is it approved for any use? No. CJC-1295 and Ipamorelin are unapproved research chemicals. They are not drugs, dietary supplements, or approved therapeutics, and they are not approved by the FDA or any comparable authority for human or veterinary use. This material is offered as a research-use-only (RUO) reagent for laboratory and educational purposes only.

How should it be stored? As a general practice for peptide reagents, the lyophilized powder is typically stored cold and protected from light and moisture -- refrigerated for shorter-term storage and frozen (e.g., -20 C or below) for longer-term storage. Any solution prepared for in-vitro work is generally kept cold and with freeze-thaw cycles minimized.

How is purity verified? Purity and identity are typically verified using HPLC (to assess percent purity) and mass spectrometry (to confirm molecular identity), with results summarized on a Certificate of Analysis (COA). Because this is a blend, a thorough COA should characterize both the CJC-1295 component -- noting whether it is the DAC or no-DAC form -- and the Ipamorelin component.

What is the difference between CJC-1295 with DAC and without DAC? They are different molecules. The no-DAC form, often labelled Modified GRF 1-29, is the 29-residue GHRH analog with an approximate molecular weight of 3,368 Da. The DAC form carries an additional Drug Affinity Complex modification that allows association with serum albumin and has a higher molecular weight of roughly 3,647 Da, with a correspondingly different persistence profile reported in preclinical models. Because the names are used inconsistently across sources, the molecular weight stated on a certificate of analysis is a more reliable identifier than the product label.

Does "5 mg + 5 mg" mean 5 mg or 10 mg of peptide in the vial? It means 5 mg of each peptide, for 10 mg of total peptide. The notation describes the amount of each component rather than a total to be divided between them. Reading it either way round is a common source of concentration errors, so the per-component figure — adjusted for the lot's stated net peptide content — is the one to use in molar calculations.

References & further reading

Related research

GLP-3 RT (Retatrutide)→ How to Read a Peptide COA→ Peptide Storage and Stability→

For Research Use Only. All Aminent Labs materials are intended solely for in-vitro research and laboratory use — not for human or veterinary use. View the product page, browse the catalog, or review certificates of analysis.